Chloronitrobenzene
Title: Chloronitrobenzene
Additional Names: Nitrochlorobenzene
Molecular Formula: C6H4ClNO2
Molecular Weight: 157.55
Percent Composition: C 45.74%, H 2.56%, Cl 22.50%, N 8.89%, O 20.31%
Literature References: Prepn of m-isomer: W. W. Hartman, M. R. Brethen, Org. Synth. coll. vol. I (2nd ed., 1964) p 162.
 
Derivative Type: m-Chloronitrobenzene
CAS Registry Number: 121-73-3
Additional Names: 1-Chloro-3-nitrobenzene; m-nitrochlorobenzene
Properties: Pale-yellow orthorhombic prisms from alcohol. d420 1.534. mp 46°. bp760 236°; bp12 117°. Insol in water. Sparingly sol in cold alcohol; freely sol in hot alcohol, chloroform, ether, carbon disulfide, glacial acetic acid.
Melting point: mp 46°
Boiling point: bp760 236°; bp12 117°
Density: d420 1.534
 
Derivative Type: o-Chloronitrobenzene
CAS Registry Number: 88-73-3
Properties: Yellow crystals. d 1.305. mp 32-33°. bp 245-246°. Insol in water. Sol in alcohol, benzene, ether.
Melting point: mp 32-33°
Boiling point: bp 245-246°
Density: d 1.305
 
Derivative Type: p-Chloronitrobenzene
CAS Registry Number: 100-00-5
Properties: Yellow crystals. d 1.520. mp 82-84°. bp 242°. Flash pt 127°C. Insol in water. Sparingly sol in cold alcohol, freely in boiling alcohol, ether, carbon disulfide.
Melting point: mp 82-84°
Boiling point: bp 242°
Flash point: Flash pt 127°C
Density: d 1.520
 
CAUTION: Absorbed by inhalation, skin penetration and ingestion. Potential symptoms of overexposure to p-isomer are anoxia; unpleasant taste; anemia; methemoglobinemia. Direct contact may cause allergic dermatitis. Potential occupational carcinogen. See NIOSH Pocket Guide to Chemical Hazards (DHHS/NIOSH 97-140, 1997) p 226; Clinical Toxicology of Commercial Products, R. E. Gosselin et al., Eds. (Williams & Wilkins, Baltimore, 5th ed., 1984) Section II, p 214, Section III, p 31-36.
Use: In dye chemistry.

Others monographs:
OlsalazineMefluidideSulfasalazinePleurotin(e)
FenpropimorphDicapthonPantetheineTacalcitol
Potassium p-AminobenzoateOil of DillAprindineDimetridazole
Pantothenic AcidTerazosinOctopamineThrombopoietin
©2016 DrugLead US FDA&EMEA